摘要
N6-methyladenosine(m6A)RNA methylation is an emerging area of epigenetics,which is a reversible and dynamic modification mediating by‘writers’(methylase,adding methyl groups,METTL3,METTL14,and WTAP),‘erasers’(demethylase,deleting methyl groups,FTO and ALKBH5),and‘readers’(YTHDF1-3,YTHDC1 and YTHDC2).Recent studies in human,animal models and cell levels have disclosed a critical role of m6A modification in regulating the homeostasis of metabolic processes and cardiovascular function.Evidence from these studies identify m6A as a candidate of biomarker and therapeutic target for metabolic abnormality and cardiovascular diseases(CVD).Comprehensive understanding of the complexity of m6A regulation in metabolic diseases and CVD will be helpful for us to understand the pathogenesis of CVD.In this review,we discuss the regulatory role of m6A in metabolic abnormality and CVD.We will emphasize the clinical relevance of m6A dysregulation in CVD.
基金
This work was supported by funding from the Innovative Research Groups of the National Natural Science Foundation of China(81521001)
Major Research Plan of the National Natural Science Foundation of China(91639104)
a grant to Aijun Sun from the National Science Fund for Distinguished Young Scholars(81725002)
National Natural Science Foundation of China(81800348)
Youth Fund of Zhongshan Hospital,Fudan University 2018ZSQN04.
